Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin pharmacokinetics and safety in dialysis patients with type 2 diabetes
ChiCTR2200062872Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) and end-stage kidney disease (ESKD) (4 arms), sponsored by Renji Hospital. Primary endpoint: Henagliflozin plasma concentration. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2200062872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062872.